Ligase Targeting Drug Development Summit on May 07-09, 2024 in Boston, United States

The development of mono- and bivalent degraders continues to gain traction, but biopharma faces challenges in rapidly discovering, validating, and utilizing novel E3 ligases. This leaves therapeutic opportunities untapped due to obstacles in ligase screening, structural characterization, and assaying therapeutic efficacy.

The Annual Ligase Targeting Drug Development Summit, now in its 4th year, will unite 80+ ligase experts dedicated to tackling ligase bottlenecks through data-driven presentations, technical discussions, and interactive sessions, unlocking the potential of E3 ligases for novel drug targets.

URLs:

Tickets: https://go.evvnt.com/2174653-2?pid=10008

Brochure: https://go.evvnt.com/2174653-3?pid=10008

Time: 9:00 AM - 5:00 PM

Prices:

Conference + Workshop - Drug Developer Pricing: USD 3598.00,

Conference Only - Drug Developer Pricing: USD 2999.00,

Conference + Workshop - Academic Pricing: USD 3098.00,

Conference Only - Academic Pricing: USD 2599.00,

Conference + Workshop - Service Provider Pricing: USD 4398.00,

Conference Only - Service Provider Pricing: USD 3699.00

Speakers: Andreas Kraemer Principal Investigator Goethe University Frankfurt am Main and Structural Genomics Consortium, Bradlee Heckmann Scientific Co-founder and Chief Scientific Officer ASHA therapeutics, Dalia Barsyte-Lovejoy Principal Investigator and Professor University of Toronto and Structural Genomics Consortium, Daniel Scott Senior Scientist St. Jude Children's Research Hospital, Gary Kleiger Chair and Professor University of Nevada, Gwenn Hansen Chief Scientific Officer Nurix Therapeutics, Jackson Gartman Senior Scientist - Chemistry Abbvie, James Papatzimas Principal Scientist Novartis, Jennifer Johnston Co Founder and Chief Executive Officer NysnoBio, Kwok-Ho Chan Investigator GSK, Levon Halabelian Principal Investigator and Assistant Professor University of Toronto and Structural Genomics Consortium, Marc Scanio Principal Research Scientist Abbvie, Marcus Hartmann Group Leader Max Planck Institute for Biology Tübingen and University of Tübingen, Oscar Huang Associate Director, Biophysics Lyterian Therapeutics, Peter Gareiss Research Investigator Arvinas, Inc., Radoslav Enchev Group Leader The Francis Crick Institute, Yongli Shan Associate Director- Discovery Biology Vicinitas Therapeutics